Bristol Myers Squibb Faces Steep Patent Cliff
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 21 2026
0mins
Should l Buy BMY?
Source: Fool
- Patent Cliff Impact: Bristol Myers Squibb faces an unusually steep patent cliff, with Revlimid sales projected to decline by 48.9% to $2.9 billion in 2025 and Sprycel sales dropping 61.7% to $493 million, directly impacting revenue and market confidence.
- Key Drug Patent Expirations: The combined sales of top drugs Eliquis and Opdivo are expected to reach $24.4 billion in 2025, accounting for nearly half of total revenue, with U.S. patent protection expiring between 2027 and 2029, leading to fierce generic competition.
- New Drug Development Potential: Despite challenges, Bristol Myers Squibb's growth portfolio saw a 23% sales increase to $16.3 billion in 2025, with Cobenfy, an innovative antipsychotic, potentially achieving $3.4 billion in annual sales by 2030 if FDA approved, which could offset future revenue losses.
- Dividend Appeal: The company currently offers a 4.2% dividend yield, with payouts consuming less than half of earnings, indicating financial stability, and providing investors with steady cash flow even amidst the looming patent cliff.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 61.730
Low
37.00
Averages
55.86
High
68.00
Current: 61.730
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Small-Cap Stocks Set for Spring Surge, Oppenheimer Says
- Alumis Outperformance: Oppenheimer identifies Alumis as a top small-cap stock, having more than doubled in 2026, reflecting strong market demand, with a price target of $55 indicating nearly 150% upside from Tuesday's close.
- Success of Envudeucitinib: Alumis's recent successful trials of its envudeucitinib drug for plaque psoriasis have bolstered analyst Jeff Jones's confidence, highlighting its biologic-like efficacy and favorable safety profile compared to first-generation alternatives.
- Optimistic Outlook for Nurix Therapeutics: Despite an 18% decline year-to-date, analyst Matthew Biegler maintains a $28 price target for Nurix, representing an 80% upside from Tuesday's close, driven by the potential of its cancer and autoimmune disease drug portfolio.
- Growth Potential of DigitalOcean: Oppenheimer views DigitalOcean as a turnaround story, with analyst Param Singh setting a $100 price target, suggesting over 16% upside from Tuesday's close, noting increasing customer demand for its AI infrastructure services.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
Bristol Myers Squibb Reports Positive Results for Heart Drug Camzyos
- Clinical Trial Results: Bristol Myers Squibb's heart drug Camzyos demonstrated significant efficacy in a Phase 3 trial involving adolescents aged 12 to 17, effectively reducing heart pressure and improving heart function and symptoms, indicating its potential to be the first approved treatment for rare heart disease in this demographic.
- Patient Improvement: Among the 44 patients in the trial, those treated with Camzyos exhibited consistent improvements across various heart performance metrics, including reduced obstruction and changes in heart structure, highlighting the drug's effectiveness and potential market in adolescent patients.
- Safety Assessment: The safety profile of Camzyos was encouraging, with side effect rates similar between the drug and placebo groups, and no new safety concerns identified during the study, further bolstering its prospects for use in younger patients.
- Future Research Plans: Bristol Myers Squibb intends to continue studying Camzyos and present longer-term results in the future; if approved by regulators, the drug could provide a new treatment option for adolescents, potentially improving symptoms and reducing the need for more invasive procedures.
See More
Camzyos Achieves Positive Results in Adolescent Hypertrophic Cardiomyopathy Trial
- Trial Success: Camzyos met its primary endpoint in the SCOUT-HCM Phase 3 trial, demonstrating a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with a least-squares mean difference of −48.0 mm Hg (P < 0.0001), indicating its potential as a treatment for adolescent hypertrophic cardiomyopathy.
- Safety Profile: The safety profile of Camzyos in adolescents was comparable to that in adults, with no new safety signals identified and no patients experiencing left ventricular ejection fraction (LVEF) below 50%, providing reassurance for its use in this population.
- Multiple Improvements: In addition to the primary endpoint, Camzyos showed significant improvements in several secondary endpoints, including LV obstruction and diastolic function, reinforcing its position as a leading treatment option for adolescents with obstructive hypertrophic cardiomyopathy.
- Future Prospects: Bristol Myers Squibb plans to present 56-week data at an upcoming medical congress, further validating the long-term efficacy and safety of Camzyos, potentially offering a paradigm-changing treatment option for adolescent patients.
See More
Impact of Trump's Tariffs One Year Later
- Widespread Tariff Impact: Trump's tariff policies have placed significant economic pressure on U.S. businesses over the past year, with approximately 80% to 85% of costs absorbed by companies, leading to reduced profits and increased consumer prices, thereby exacerbating overall economic uncertainty.
- Retail Sector Adaptation: While large retailers like Walmart have emerged relatively unscathed, smaller businesses have been severely impacted, with Home Depot aiming to limit purchases from any single country to 10% to reduce dependency and enhance supply chain flexibility.
- Automotive Industry Cost Surge: Automakers such as General Motors and Toyota are facing tariff impacts estimated at up to $9.5 billion, and although the Trump administration has taken steps to alleviate overlapping tariffs, overall costs remain significant, forcing companies to reassess their supply chain strategies.
- Pharmaceutical Sector Stability: Pharmaceutical companies have secured three-year tariff exemptions through pricing agreements with Trump, although new tariffs impose 100% on companies that do not reach agreements, the overall industry is still striving to increase investments in U.S. manufacturing.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Small-Cap Stocks Set for Spring Surge, Oppenheimer Says
- Alumis Outperformance: Oppenheimer identifies Alumis as a top small-cap stock, having more than doubled in 2026, reflecting strong market demand, with a price target of $55 indicating nearly 150% upside from Tuesday's close.
- Success of Envudeucitinib: Alumis's recent successful trials of its envudeucitinib drug for plaque psoriasis have bolstered analyst Jeff Jones's confidence, highlighting its biologic-like efficacy and favorable safety profile compared to first-generation alternatives.
- Optimistic Outlook for Nurix Therapeutics: Despite an 18% decline year-to-date, analyst Matthew Biegler maintains a $28 price target for Nurix, representing an 80% upside from Tuesday's close, driven by the potential of its cancer and autoimmune disease drug portfolio.
- Growth Potential of DigitalOcean: Oppenheimer views DigitalOcean as a turnaround story, with analyst Param Singh setting a $100 price target, suggesting over 16% upside from Tuesday's close, noting increasing customer demand for its AI infrastructure services.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
Bristol Myers Squibb Reports Positive Results for Heart Drug Camzyos
- Clinical Trial Results: Bristol Myers Squibb's heart drug Camzyos demonstrated significant efficacy in a Phase 3 trial involving adolescents aged 12 to 17, effectively reducing heart pressure and improving heart function and symptoms, indicating its potential to be the first approved treatment for rare heart disease in this demographic.
- Patient Improvement: Among the 44 patients in the trial, those treated with Camzyos exhibited consistent improvements across various heart performance metrics, including reduced obstruction and changes in heart structure, highlighting the drug's effectiveness and potential market in adolescent patients.
- Safety Assessment: The safety profile of Camzyos was encouraging, with side effect rates similar between the drug and placebo groups, and no new safety concerns identified during the study, further bolstering its prospects for use in younger patients.
- Future Research Plans: Bristol Myers Squibb intends to continue studying Camzyos and present longer-term results in the future; if approved by regulators, the drug could provide a new treatment option for adolescents, potentially improving symptoms and reducing the need for more invasive procedures.
See More
Camzyos Achieves Positive Results in Adolescent Hypertrophic Cardiomyopathy Trial
- Trial Success: Camzyos met its primary endpoint in the SCOUT-HCM Phase 3 trial, demonstrating a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with a least-squares mean difference of −48.0 mm Hg (P < 0.0001), indicating its potential as a treatment for adolescent hypertrophic cardiomyopathy.
- Safety Profile: The safety profile of Camzyos in adolescents was comparable to that in adults, with no new safety signals identified and no patients experiencing left ventricular ejection fraction (LVEF) below 50%, providing reassurance for its use in this population.
- Multiple Improvements: In addition to the primary endpoint, Camzyos showed significant improvements in several secondary endpoints, including LV obstruction and diastolic function, reinforcing its position as a leading treatment option for adolescents with obstructive hypertrophic cardiomyopathy.
- Future Prospects: Bristol Myers Squibb plans to present 56-week data at an upcoming medical congress, further validating the long-term efficacy and safety of Camzyos, potentially offering a paradigm-changing treatment option for adolescent patients.
See More
